Acute Severe Ulcerative Colitis: Review of Management and Emerging Treatments
Canadian IBD Today · 2024
DOI: 10.58931/cibdt.2024.2229 ↗Kurz gefasst
Fachartikel in der Zeitschrift Canadian IBD Today, 2024. Verfasst von Natasha Klemm und 1 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Acute severe ulcerative colitis (ASUC) is a medical emergency, with an overall mortality rate of 1%. Patients with ulcerative colitis (UC) have a 20–25% rate of severe exacerbation requiring hospitalization for urgent medical treatment and surgical consideration. The rate of re-hospitalization for recurrent ASUC is 34.4%, and it typically occurs within 24 months of the index admission. Treatment requires a patient-centred multidisciplinary approach that includes gastroenterology, colorectal surgery, and nutrition support, with the goal of minimizing disease complications, adverse events of treatment, and healthcare costs.6 Clinicians and patients have an increasing number of treatment options and additional safety issues to consider. We review the current approach to management and summarize emerging data on the use of novel agents to treat ASUC.
Zitieren
APA
Klemm, N., & Leung, Y. (2024). Acute Severe Ulcerative Colitis: Review of Management and Emerging Treatments. Canadian IBD Today. https://doi.org/10.58931/cibdt.2024.2229
Vancouver
Klemm N, Leung Y. Acute Severe Ulcerative Colitis: Review of Management and Emerging Treatments. Canadian IBD Today. 2024. doi:10.58931/cibdt.2024.2229
BibTeX
@article{Klemm2024,
author = {Klemm, Natasha and Leung, Yvette},
title = {Acute Severe Ulcerative Colitis: Review of Management and Emerging Treatments},
journal = {Canadian IBD Today},
year = {2024},
doi = {10.58931/cibdt.2024.2229}
}
EUVIMED